Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / Hanmi acquires Aptose Biosciences
Business acquisition

Hanmi acquires Aptose Biosciences

Analysis based on 6 articles · First reported Jun 30, 2026 · Last updated Jun 30, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition of Aptose Biosciences by Hanmi Pharm is a positive development for Aptose Biosciences shareholders, who received a 28% premium. It signifies consolidation in the biotechnology and pharmaceutical sectors, potentially impacting investor sentiment towards similar clinical-stage oncology companies.

biotechnology pharmaceuticals
Event Summary

Hanmi Pharm, through its subsidiary North American Cobalt Inc., has completed the acquisition of Aptose Biosciences for C$2.41 per common share. This represents a 28% premium over Aptose Biosciences's 30-day volume-weighted average price on the Toronto Stock Exchange. The arrangement received shareholder and court approval on March 31, 2026, and regulatory approvals in South Korea. As a result, Aptose Biosciences's common shares are expected to be delisted from the Toronto Stock Exchange around July 3, 2026, and the company will terminate its public reporting requirements in Canada and the United States. This acquisition strengthens Hanmi Pharm's oncology pipeline with Aptose Biosciences's lead compound, tuspetinib.

Key Actions
100 Hanmi Pharm acquired Aptose Biosciences
70 Aptose Biosciences received approval
60 Aptose Biosciences submitted application
Entities Involved
stock
Aptose Biosciences
Aptose Biosciences was acquired by Hanmi Pharm for C$2.41 per share, representing a 28% premium. Its common shares are expected to be delisted from the Toronto Stock Exchange.
Importance 100.0 Sentiment 70.0
stock
Hanmi Pharm
Hanmi Pharm, through its subsidiary North American Cobalt Inc., successfully acquired Aptose Biosciences, expanding its oncology pipeline.
Importance 100.0 Sentiment 60.0
priv
North American Cobalt Inc.
North American Cobalt Inc., a wholly owned subsidiary of Hanmi Pharm, was the direct purchaser of Aptose Biosciences's common shares.
Importance 80.0 Sentiment 60.0
exch
Toronto Stock Exchange
The common shares of Aptose Biosciences are expected to be delisted from the Toronto Stock Exchange following the acquisition.
Importance 20.0 Sentiment 0.0
cnt
United States
Aptose Biosciences has submitted an application to terminate its public reporting requirements in the United States.
Importance 10.0 Sentiment 0.0
cnt
South Korea
The acquisition received necessary regulatory approvals in South Korea.
Importance 10.0 Sentiment 0.0
cnt
Canada
The acquisition involved Canadian securities laws and the delisting of Aptose Biosciences from a Canadian exchange.
Importance 10.0 Sentiment 0.0
Relationships
North American Cobalt Inc. related ↔ United States
North American Cobalt Inc. related ↔ South Korea
North American Cobalt Inc. related ↔ Canada
Toronto Stock Exchange related ↔ United States
Toronto Stock Exchange related ↔ Canada
United States related ↔ South Korea
United States strained-ally ↔ Canada The United States has severely strained its historically close relationship with Canada by imposing sweeping tariffs and
South Korea related ↔ Canada
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.